Immune cell therapy shows promise for Tough-to-Treat autoimmune diseases

NCT ID NCT06255028

First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This early-stage study tests a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target and destroy faulty B cells that drive the disease. The main goals are to check safety and find the right dose, with only 6 participants enrolled so far.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fred Hutch

    Seattle, Washington, 98109, United States

  • Keck School of Medicine of University of Southern California

    Los Angeles, California, 90033, United States

  • Lurie Children's; Northwestern Medicine - Northwestern Medical Group

    Chicago, Illinois, 60611, United States

  • Primary Children's Hospital

    Salt Lake City, Utah, 84113, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • UC Davis

    Sacramento, California, 957817, United States

Conditions

Explore the condition pages connected to this study.